Latest filing published 24 Jan 2023 for Apellis Pharmaceuticals, Inc., €68k.
Filing timeline
BuySaleInsider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Victoria L. Brown: trading record in brief
Victoria L. Brown (chief executive) discloses dealings in Apellis Pharmaceuticals, Inc. to SEC (Form 4). Between 7 October 2020 and 20 January 2023, the trades on record add up to 14 filings.
No open-market purchase appears, only 2 sales worth €472k. Besides market trades, the filings include 11 share grants and 1 option exercise.
The record was last updated on 24 January 2023 with a share grant (€68k) in Apellis Pharmaceuticals, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Victoria L. Brown
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 1,412 shares@ US$52.0590.0% of flowCommon StockSEC:0001127602-23-002109:0
- 130 shares@ US$58.4110.0% of flowCommon StockSEC:0000899243-22-034414:0
- 2,698 shares@ US$45.000.0022% mcap73.8% of flowCommon StockSEC:0001127602-22-017990:0
- 82 shares@ US$49.282.6% of flowCommon StockSEC:0001127602-22-010532:0
- 175 shares@ US$47.125.1% of flowCommon StockSEC:0001127602-22-004777:0
- 434 shares@ US$38.5910.7% of flowCommon StockSEC:0001127602-22-002817:0
- 17,466 shares0Common StockSEC:0001127602-22-002058:0
- 882 shares0Common StockSEC:0001127602-21-027695:0
8 of 8 declarations
